Phosphorylated heterodimers of ERBB2 KD mutants and EGFR bind GRB2:SOS1

Stable Identifier
R-HSA-9665000
Type
Reaction [binding]
Species
Homo sapiens
Compartment
cytosol, plasma membrane
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Phosphorylated heterodimers of ERBB2 KD mutants and EGFR bind GRB2:SOS1
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

The following EGFR-binding ERBB2 KD mutants that were shown to activate RAS/RAF/MAPK signaling, evidenced by activating phosphorylation of ERKs (MAPK1 and MAPK3), are assumed to, like the wild type ERBB2:EGFR heterodimer, directly bind to the GRB2:SOS1 complex:

ERBB2 L755S (Trowe et al. 2008, Kancha et al. 2011, Bose et al. 2013, Cocco et al. 2018);
ERBB2 L755P (Kancha et al. 2011);
ERBB2 I767M (Ng et al. 2015; binding to EGFR indirectly demonstrated by Bose et al. 2013);
ERBB2 D769H (Bose et al. 2013);
ERBB2 V777L (Kancha et al. 2011, Bose et al. 2013);
ERBB2 P780_Y781insGSP (Suzawa et al. 2016);
ERBB2 T798M (Kancha et al. 2011, Rexer et al. 2013);
ERBB2 T798I (Hanker et al. 2017);
ERBB2 V842I (Bose et al. 2013);
ERBB2 T862A (Kancha et al. 2011);
ERBB2 H878Y (Kancha et al. 2011, Hu, Hu et al. 2015, Hu, Wan et al. 2015);
ERBB2 R896C (Bose et al. 2013);
ERBB2 L755_T759del (Bose et al. 2013);
ERBB2 A775_G776insYVMA (Wang et al. 2006);

Activation of RAS/RAF/MAPK signaling downstream of the following ERBB2 KD cancer mutants has not been studied and they are annotated as candidates:

ERBB2 L755M
ERBB2 L755W
ERBB2 D769Y
ERBB2 D769N
ERBB2 V777M
ERBB2 V777E
ERBB2 T733I
ERBB2 V842E
ERBB2 H878R
ERBB2 R896H
ERBB2 G778_P780insGSP
ERBB2 A771_Y772insYVMA

Literature References
PubMed ID Title Journal Year
16843263 HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Wang, SE, Narasanna, A, Perez-Torres, M, Xiang, B, Wu, FY, Yang, S, Carpenter, G, Gazdar, AF, Muthuswamy, SK, Arteaga, CL

Cancer Cell 2006
18413839 EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation

Trowe, T, Boukouvala, S, Calkins, K, Cutler, RE, Fong, R, Funke, R, Gendreau, SB, Kim, YD, Miller, N, Woolfrey, JR, Vysotskaia, V, Yang, JP, Gerritsen, ME, Matthews, DJ, Lamb, P, Heuer, TS

Clin. Cancer Res. 2008
26375550 Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor

Hu, Z, Hu, Y, Liu, X, Xi, R, Zhang, A, Liu, D, Xie, Q, Chen, L

Oncotarget 2015
22046346 Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib

Kancha, RK, von Bubnoff, N, Bartosch, N, Peschel, C, Engh, RA, Duyster, J

PLoS ONE 2011
25994018 Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification

Ng, CK, Martelotto, LG, Gauthier, A, Wen, HC, Piscuoglio, S, Lim, RS, Cowell, CF, Wilkerson, PM, Wai, P, Rodrigues, DN, Arnould, L, Geyer, FC, Bromberg, SE, Lacroix-Triki, M, Penault-Llorca, F, Giard, S, Sastre-Garau, X, Natrajan, R, Norton, L, Cottu, PH, Weigelt, B, Vincent-Salomon, A, Reis-Filho, JS

Genome Biol. 2015
26545934 Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations

Suzawa, K, Toyooka, S, Sakaguchi, M, Morita, M, Yamamoto, H, Tomida, S, Ohtsuka, T, Watanabe, M, Hashida, S, Maki, Y, Soh, J, Asano, H, Tsukuda, K, Miyoshi, S

Cancer Sci. 2016
25853726 Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity

Hu, Z, Wan, X, Hao, R, Zhang, H, Li, L, Li, L, Xie, Q, Wang, P, Gao, Y, Chen, S, Wei, M, Luan, Z, Zhang, A, Huang, N, Chen, L

PLoS ONE 2015
28274957 An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer

Hanker, AB, Brewer, MR, Sheehan, JH, Koch, JP, Sliwoski, GR, Nagy, R, Lanman, R, Berger, MF, Hyman, DM, Solit, DB, He, J, Miller, V, Cutler, RE, Lalani, AS, Cross, D, Lovly, CM, Meiler, J, Arteaga, CL

Cancer Discov 2017
23948973 Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2

Rexer, BN, Ghosh, R, Narasanna, A, Estrada, MV, Chakrabarty, A, Song, Y, Engelman, JA, Arteaga, CL

Clin. Cancer Res. 2013
30301790 Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

Cocco, E, Javier Carmona, F, Razavi, P, Won, HH, Cai, Y, Rossi, V, Chan, C, Cownie, J, Soong, J, Toska, E, Shifman, SG, Sarotto, I, Savas, P, Wick, MJ, Papadopoulos, KP, Moriarty, A, Cutler, RE, Avogadri-Connors, F, Lalani, AS, Bryce, RP, Chandarlapaty, S, Hyman, DM, Solit, DB, Boni, V, Loi, S, Baselga, J, Berger, MF, Montemurro, F, Scaltriti, M

Sci Signal 2018
23220880 Activating HER2 mutations in HER2 gene amplification negative breast cancer

Bose, R, Kavuri, SM, Searleman, AC, Shen, W, Shen, D, Koboldt, DC, Monsey, J, Goel, N, Aronson, AB, Li, S, Ma, CX, Ding, L, Mardis, ER, Ellis, MJ

Cancer Discov 2013
Participants
Input
Output
Participant Of
hasEvent
Normal reaction
GRB2:SOS1 complex binds phosphorylated EGFR:ERBB2 heterodimer (Homo sapiens)
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Orlic-Milacic, M  (2019-07-31)
Reviewed
Kancha, RK  (2019-09-16)
Created
Orlic-Milacic, M  (2019-10-28)